Lesinurad: A Selective Uric Acid Reabsorption Inhibitor for Gout
Lesinurad, originally developed by Ardea Biosciences, was acquired by AstraZeneca through the acquisition of Ardea in June 2012. It works to reduce the uric acid levels in gout patients.